Company news
Femasys Inc. news in 2026
Femasys Inc.'s news releases, calls and decks from 2026, newest first.
Femasys Appoints John Moorhead to Board of Directors
October 30, 2026
Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs
October 20, 2026
Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control
October 14, 2026
Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo
October 8, 2026
Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care
September 15, 2026
Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio
September 9, 2026
Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations
August 26, 2026
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
August 19, 2026
Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
August 14, 2026
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
August 12, 2026
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million
August 7, 2026
Femasys Regains Compliance with Nasdaq Listing Requirements
June 23, 2026
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter
May 13, 2026
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update
May 8, 2026
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete
May 5, 2026
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026
April 22, 2026
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio
April 16, 2026
Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
March 31, 2026
Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
March 30, 2026
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors
March 17, 2026
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
March 10, 2026
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 27, 2026
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access
February 25, 2026
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination
February 22, 2026
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
February 3, 2026
Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
January 14, 2026
Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care
January 13, 2026
Decks in 2026
- Investor Presentation (May 2026)
Investor deck · 24 slides · May 13, 2026